pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 19, Issue 7, 2003, Pages 543-550

  Brandin, Eleonor ^a,d   Lindborg, Lena ^a   Gyllensten, Katarina ^a   Broström, Christina ^a   Hagberg, Lars ^b   Gisslen, Magnus ^a   Tuvesson, Björn ^c   Blaxhult, Anders ^a   Albert, Jan ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINGBORG HOSPITAL   (Sweden)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ADULT; ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURAL GENE; SWEDEN; TREATMENT FAILURE; VIROLOGY; VIRUS RESISTANCE;

EID: 0041366926     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322230905     Document Type: Article

References (22)

1. Andreasson PA, Dias F, Naucler A, et al.: A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993;7:989-993.
2. De Cock KM, Adjorlolo G, Ekpini E, et al.: Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 1993;270:2083-2086.
3. Kanki PJ, Travers KU, Mboup, S, et al.: Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-946.
4. Marlink R, Kanki P, Thior I, et al.: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-1590.
5. van der Ende ME, Guillon C, Boers PH, et al.: Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquit Immune Defic Syndr 2000;25:11-18.
6. van der Ende ME, Schutten M, Ly TD, et al.: HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996;10:1649-1655.
7. Rodes B, Holguin A, Soriano V, et al.: Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000;38:1370-1374.
8. Smith NA, Shaw T, Berry N, et al.: Antiretroviral therapy for HIV-2-infected patients. J Infect 2001;42:126-133.
9. Soriano V, Gomes P, Heneine W, et al.: Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000;61:111-116.
10. Isaka Y, Miki S, Kawauchi S, et al.: Isolation and characterization of simian immunodeficiency virus variants that are resistant to non-nucleoside reverse transcriptase inhibitors. Arch Virol 2000;145:2481-2492.
11. Witvrouw M, Pannecouque C, Van Laethem K, et al.: Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999;13:1477-1483.
12. Yeni PG, Hammer SM, Carpenter CC, et al.: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002;288:222-235.
13. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAMA 2000;283:2417-2426.
14. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.
15. Leitner T, Korovina G, Marquina S, et al.: Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. AIDS Res Hum Retroviruses 1996;12:1595-1603.
16. Andersson S, Norrgren HI, da Silva Z, et al.: Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000;160:3286-3293.
17. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999;41:95-98.
18. van de Peer Y, De Wachter R: TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 1994;10:569-570.
19. Allen MI, Deslauriers M, Andrews CW, et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
20. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180.
21. Van Rompay KK, Greenier JL, Marthas ML, et al.: A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother 1997;41:278-283.
22. CDC: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.